Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LNTH vs BMRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LNTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)
LNTH Overall Winner
6-Pillar Tally: LNTH 6 – 0 BMRA
Matrix Metrics: LNTH 9 – 1 BMRA
As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LNTH carries a Unified Composite Score of 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).
- Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY).
- Technical & Structure Timing Caution: LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About LNTH vs BMRA
LNTH
Head-to-Head Winner
Lantheus Holdings, Inc
$101.75
+0.16% 1D
Market Cap
$6.6B
TTM Revenue
$1.56B
Forward P/E
15.4x
Beta / 30D Vol
0.45β · 5% Vol
Unified Composite Score
43.5
HOLD
Tech 42.0
Fund 49.0
Flow 58.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
BMRA
Biomerica Inc
$1.33
-2.32% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (LNTH 6 – 0 BMRA)
1. Valuation Multiples
LNTH
Forward P/E
15.4x
N/M
Trailing P/E
25.3x
N/M
PEG Ratio
0.61x
N/M
EV / Revenue
4.2x
1.1x
2. Growth & Scale
LNTH
Revenue Growth (YoY)
+1.5%
-8.3%
Earnings Growth (YoY)
-19.5%
+0.0%
TTM Revenue (USD)
$1.56B
$4.3M
Market Cap
$6.6B
$6.0M
3. Profitability & Quality
LNTH
Gross Margin
61.3%
0.9%
Operating Margin
16.9%
-125.2%
Net Profit Margin
17.3%
-115.5%
Return on Equity (ROE)
21.8%
-113.8%
4. Balance Sheet & Cash Flow
LNTH
Cash Generation (TTM)
$387M
-$3.2M
Cash Flow Margin
24.8%
-73.5%
Net Cash / Leverage
$59M Net Cash
$1.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
LNTH
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
7.2% (4th %ile)
N/A (N/A)
Put/Call OI Skew
0.87x (Balanced)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
LNTH
OpEx & R&D Intensity
44.4% of Rev ($694M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: LNTH (9) vs BMRA (1)| Institutional Metric | LNTH | BMRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.6B | $6.0M | LNTH | |
| Trailing P/E Ratio | 25.3x | N/M | LNTH | |
| Forward P/E Ratio | 15.4x | N/M | LNTH | |
| Revenue Growth (YoY) | +1.5% | -8.3% | LNTH | |
| Operating Margin (TTM) | 16.9% | -125.2% | LNTH | |
| Net Profit Margin | 17.3% | -115.5% | LNTH | |
| Return on Equity (ROE) | 21.8% | -113.8% | LNTH | |
| 52-Week Range Position | 83% ($51–$112) | 4% ($1–$3) | LNTH | |
| Beta / 30D Volatility | 0.45β · 5% Vol | 0.67β · 62% Vol | LNTH | |
| Unified Institutional Score | 43.5 / 100 (HOLD) | 44.5 / 100 (HOLD) | BMRA | |
| Trailing 12M Revenue (USD) | $1.56B | $4.3M | Scale | |
| Gross Profit Margin (TTM) | 61.3% | 0.9% | Quality | |
| PEG Ratio & EV / Revenue | 0.61x PEG · 4.2x EV/Rev | N/M PEG · 1.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $387M ($59M Net Cash) | -$3.2M ($1.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
LNTH +30.25 pp
3M Horizon
LNTH +18.46 pp
6M Horizon
LNTH +50.22 pp
1Y Horizon
LNTH +138.42 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LNTH Revenue | BMRA Revenue | LNTH Op. Margin | BMRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $350M | $10M | 14.9% | -46.4% | LNTH |
| FY2020 | $340M | $10M | -1.2% | -41.0% | LNTH |
| FY2021 | $430M | $10M | -14.3% | -104.2% | LNTH |
| FY2022 | $940M | $20M | 3.9% | -24.0% | LNTH |
| FY2023 | $1.30B | $10M | 28.1% | -135.3% | LNTH |
| FY2024 | $1.53B | $10M | 29.8% | -117.6% | LNTH |
| FY2025 | $1.54B | $10M | 20.2% | -96.7% | LNTH |
| FY2026 | N/A | $0M | N/A | -119.5% | BMRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
LNTH
CONSOLIDATION
Current IV
7.2%
IV Percentile
4th %ile
Put/Call OI Skew
0.87x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact LNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
LNTH Moat Profile
Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
44.4% of Rev ($694M)
90D Engineering Disclosures
0 Published
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ LNTH vs BMRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LNTH carries a Unified Composite Score of 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY). Technical & Structure Timing Caution: LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LNTH leads the Growth & Scale pillar: LNTH posts +1.5% YoY revenue growth and -19.5% YoY earnings growth on $1.56B TTM revenue (61.3% gross margin, 16.9% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), LNTH cumulative revenue shifted +340.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, LNTH deploys 44.4% of Rev ($694M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.
LNTH screens cheaper on headline valuation multiples. LNTH trades at 15.4x Forward P/E, 25.3x Trailing P/E, 0.61x PEG, and 4.2x EV/Revenue (24.8% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LNTH (21.8% ROE) versus BMRA (-113.8% ROE) capital efficiency.
In options market volatility and institutional positioning, LNTH carries 7.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.87x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.45β · 5% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BMRA vs LNTH · Reverse Pair
LNTH vs MEDP
· Sector Peer
LNTH vs LIVN
· Sector Peer
LNTH vs KRYS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking